Adjuvant Treatment of Prostate Cancer With Docetaxel or Not After Radical Radiotherapy

Summary

As docetaxel is proven to be effective in late stages of prostate cancer with a large tumour burden it should be effective in primarily treated intermediate and high risk prostate cancer as an adjuvant treatment after radiotherapy to prevent early relapse. This will therefore be tested in a randomised phase III trial where patients will be randomized either to docetaxel or surveillance

Timeline

Start

2007-05

Primary completion

2023-08-30

Completion

2023-08-30

Drugs

Indications